ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0655

Relationship Between Patient-Reported Outcomes to Hospitalization in Patients Living with SLE: A Retrospective Cohort Study Utilizing the FORWARD Lupus Registry

Minjee Park1, Sofia Pedro2, Jean-Francois Ricci1, Kaleb Michaud3 and Patti Katz4, 1Alira Health, Basel, Switzerland, 2Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 3University of Nebraska Medical Center, Omaha, NE, 4UCSF, San Rafael, CA

Meeting: ACR Convergence 2024

Keywords: Disease Activity, registry, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease with diverse symptoms and multisystemic manifestations. Reducing exacerbations (flares), often leading to hospitalization, remains a challenge in the care of patients with SLE. This study aims to understand the association of validated Patient Reported Outcomes (PROs) such as Systemic Lupus Activity Questionnaire (SLAQ) and Brief Index of Lupus Damage (BILD) to hospitalization.

Methods: The FORWARD Lupus Registry (FLR) is a US longitudinal patient-reported registry, collected through FORWARD, The National Databank for Rheumatic Diseases. Patients with at least two consecutive FLR biannual surveys who completed age, sex, SLAQ, SLAQ flare component, and BILD at baseline and hospitalization (emergency room (ER) and/or all-cause hospitalization) at their consecutive biannual survey were included. Descriptive analyses were conducted on socio-demographics, disease characteristics, Rheumatic Disease Comorbidity Index (RDCI), and treatment at baseline, stratified by hospitalization (0 or 1+). Group differences were assessed using t-test and Chi-square tests (or Fisher’s exact test), when appropriate. Three distinct multivariate logistic regression models examined the relationship of prior SLAQ score, SLAQ flare component, BILD score to hospitalization, individually, and adjusting for potential confounders (age, sex, insurance type, total annual income, RDCI, and treatments).

Results: Out of 383 FLR patients, 98 (25.6%) had an ER visit or all-cause hospitalization in their consecutive biannual survey (22.7% ER, 13.8% all cause-hospitalization, 11% both from the total). The mean BILD and SLAQ score were significantly higher in the ≥ 1 Hospitalization group (BILD: 4.21 (SD 2.43) vs 3.18 (SD 2.03), p< 0.001 ; SLAQ: 14.45 (SD 7.99) vs 9.79 (SD 6.68), p < 0.001), with more flares reported through the SLAQ flare component (70% vs 51%, p< 0.001) (Table 1). SLAQ score and SLAQ flare component were significant predictors of hospitalization in their respective models (OR=1.07; 95%CI: 1.02-1.11, OR=2.26; 95%CI: 1.24-4.14), while BILD score showed a similar trend but was not statistically significant (OR=1.10; 95%CI: 0.96-1.27). RDCI was a statistically significant predictor of hospitalization in all three multivariate models, increasing the odds of hospitalization (OR=1.33, 95%CI 1.15-1.54, OR=1.25, 95%CI 1.07-1.46, OR=1.29; 95%CI: 1.11-1.51).

Conclusion: SLE patients with higher SLAQ score, or having any flare reported by the SLAQ flare component irrespective of the severity are at higher risk of hospitalization. Patient-reported disease activity should be considered in clinical setting for the evaluation of SLE patients and the management of lupus to minimize frequency of flares. 

Supporting image 1


Disclosures: M. Park: None; S. Pedro: None; J. Ricci: Janssen, 2, Novartis, 2, Roche, 3, UCB, 2; K. Michaud: None; P. Katz: None.

To cite this abstract in AMA style:

Park M, Pedro S, Ricci J, Michaud K, Katz P. Relationship Between Patient-Reported Outcomes to Hospitalization in Patients Living with SLE: A Retrospective Cohort Study Utilizing the FORWARD Lupus Registry [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/relationship-between-patient-reported-outcomes-to-hospitalization-in-patients-living-with-sle-a-retrospective-cohort-study-utilizing-the-forward-lupus-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/relationship-between-patient-reported-outcomes-to-hospitalization-in-patients-living-with-sle-a-retrospective-cohort-study-utilizing-the-forward-lupus-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology